Last reviewed · How we verify
Choletec (TECHNETIUM TC 99M MEBROFENIN)
At a glance
| Generic name | TECHNETIUM TC 99M MEBROFENIN |
|---|---|
| Sponsor | Bracco |
| Drug class | Radioactive Diagnostic Agent |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
| First approval | 1987 |
Approved indications
- Hepatobiliary imaging
Common side effects
- Multiple use of single-use product
- Therapeutic product effect decreased
Key clinical trials
- Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Choletec CI brief — competitive landscape report
- Choletec updates RSS · CI watch RSS
- Bracco portfolio CI